drugset / Trial / NCT05765955
Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses
RandomizedParallel-groupDouble-blindTreatment
Summary
A single center trial to evaluate the effect of POLB 001 on inflammatory responses following an intradermal LPS challenge in healthy volunteers.
Timeline
- Start
- 2022-07-22
- Primary completion
- 2022-12-14
- Completion
- 2022-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | POLB 001 | Unknown | 30 mg | — |
| Comparator | POLB 001 | Unknown | 70 mg | — |
| Comparator | POLB 001 | Unknown | 150 mg | — |